1. Rise in neonatal abstinence syndrome rate is associated with increase in buprenorphine prescription numbers;South Med J
2. US Food and Drug Administration. FDA analysis of long-term trends in prescription opioid analgesic products: quantity, sales, and price trends. https://www.fda.gov/files/about%20fda/published/FDA-Analysis-of-Long-Term-Trends-in-Prescription-Opioid-Analgesic-Products--Quantity--Sales--and-Price-Trends.pdf. Published March 1, 2018. Accessed May 3, 2024.
3. American College of Obstetrics and Gynecology, Committee on Obstetric Practice; American Society of Addiction Medicine. Opioid use and opioid use disorder in pregnancy. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy. Published August 2017. Accessed March 28, 2024.
4. Prevention of neonatal abstinence syndrome in an outpatient prenatal buprenorphine tapering program;South Med J